{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:22:41Z","timestamp":1781904161288,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.clml.2013.04.006","type":"journal-article","created":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T21:25:02Z","timestamp":1371245102000},"page":"575-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Single-Arm, Phase II Study of the Anti-Blys Monoclonal Antibody Belimumab in Symptomatic Waldenstrom Macroglobulinemia"],"prefix":"10.1016","volume":"13","author":[{"given":"Mark","family":"Bishton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.04.006_bib1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","article-title":"The TNF and TNF receptor superfamilies: integrating mammalian biology","volume":"104","author":"Locksley","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.clml.2013.04.006_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: a tutorial on B\u00a0cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clml.2013.04.006_bib3","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLYS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2013.04.006_bib4","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clml.2013.04.006_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/79802","article-title":"APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity","volume":"1","author":"Yu","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2013.04.006_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/76889","article-title":"Identification of a receptor for BLYS demonstrates a crucial role in humoral immunity","volume":"1","author":"Yan","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2013.04.006_bib7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/89790","article-title":"Activation and accumulation of B cells in TACI-deficient mice","volume":"2","author":"Yan","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2013.04.006_bib8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clml.2013.04.006_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","article-title":"B\u00a0cell development pathways","volume":"19","author":"Hardy","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clml.2013.04.006_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLYS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.clml.2013.04.006_bib11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.194.11.1691","article-title":"Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen","volume":"194","author":"Schneider","year":"2001","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2013.04.006_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B\u00a0cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLYS","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2013.04.006_bib13","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1126\/science.1061964","article-title":"An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway","volume":"293","author":"Schiemann","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clml.2013.04.006_bib14","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2013.04.006_bib15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2013.04.006_bib16","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2013.04.006_bib17","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2005-09-3552","article-title":"B-lymphocyte stimulator (BLYS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia","volume":"107","author":"Elsawa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.006_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3816\/CLM.2006.n.013","article-title":"Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia","volume":"6","author":"Kimby","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2013.04.006_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/ar2506","article-title":"Biologic activity and safety of belimumab, a\u00a0neutralizing anti-B-lymphocyte stimulator (BLYS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus","volume":"10","author":"Furie","year":"2008","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:02Z","timestamp":1761870302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013001249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S2152265013001249"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.04.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Single-Arm, Phase II Study of the Anti-Blys Monoclonal Antibody Belimumab in Symptomatic Waldenstrom Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}